Relationship of Glycemia to Cardiovascular Disease ... - Lipids Online

APPROACH: Primary Endpoint:
Change in Percent Atheroma Volume
Change in Percent
Atheroma Volume (%)
0.5
0.4
0.3
0.2
0.1
0.0
-0.1
-0.2
-0.3
0.43 (−0.22,(
1.08) P = 0.19
Glipizide
N = 462
Treatment Difference
−0.64 (−1.46,(
0.17)
P = 0.12
Rosiglitazone
−0.21 (−0.86,(
0.44) P = 0.53
Nesto RW, et al, for the APPROACH Study Group.
Circulation. 2008;118:2313. Abstract #5221.
Slide Source
Lipids Online Slide Library
www.lipidsonline.org
APPROACH: Primary Endpoint: Change in Percent Atheroma Volume
The primary endpoint, change in percent atheroma volume, was −0.21% in the
rosiglitazone group versus 0.43% in the glipizide group (p = 0.12 between groups).
By looking at the results of the PERISCOPE trial and the APPROACH trial together, and
evaluating the relative benefits of thiazolidinediones against sulfonylureas with regard to
progression of atherosclerosis, a virtual “head-to-head” comparison of these two agents
was made. The resulting data were interesting in view of the debate over the past year of
whether rosiglitazone and pioglitazone have different properties that might either increase
or reduce the risk of cardiovascular events.
APPROACH = Assessment on the Prevention of Progression by Rosiglitazone on
Atherosclerosis in diabetes patients with Cardiovascular History
Reference:
Nesto RW, Cannon CP, Gerstein HC, et al, for the APPROACH Study Group. Results of
the APPROACH trial: assessment on the prevention of progression by rosiglitazone on
atherosclerosis in type 2 diabetes patients with cardiovascular history. Circulation.
2008;118:2313. Abstract #5221.
Source: Lipids Online Slide Library (www.lipidsonline.org) Page 30 of 36
© 2009 Baylor College of Medicine, Houston, Texas